Clareo Health | An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celltrion
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient who has completed the scheduled visits, including the End-of-Study Visit, in Study CT-P13 3.1
Patient who has not had any major protocol violation in Study CT-P13 3.1
Patient is permitted to enter the extension study if, in the option of their general practitioner or the investigator, the patient will continue to gain benefit from treatment in the extension study. Local guidelines for patient treatment will be followed
You may not be if
Patient who has been withdrawn from Study CT-P13 3.1 for any reason
Patient who, at the time of providing informed consent, has any ongoing medical issues such as serious adverse events (SAEs) or intolerance issues that mean continuation in this extension study could be detrimental to their health, in the opinion of the investigator
Patient who plans to participate in a study with an investigational drug during the period of this extension study
